Phathom Pharmaceuticals PHAT 深 沪
已收盘 01-09 16:00:00 美东时间
15.015
-0.585
-3.75%
华盛通- 最 高15.74
- 今 开15.60
- 成交量 153.28万股
- 最 低 14.77
- 昨 收 15.60
- 总市值 10.68亿
- 52周最高 18.31
- 市盈率 静 --
- 换手率 2.15%
- 52周最低 2.21
- 委 比 46.45%
- 总股本 7113.84万
- 历史最高 64.54
- 量 比 0.80
- 振 幅 6.22%
- 历史最低 2.21
- 每 手 1
- 风险率 4.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phathom's Early Numbers Show Sales Strength, Eyes 2026 Profitability
Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
01-08 21:49
Phantom slumps 12%; prices $130M stock at $16 per share
Phathom Pharmaceutical (PHAT) priced an underwritten public offering of ~6.88M shares and pre-funded warrants to purchase ~1.25M shares. The shares of common stock are being sold to the public at a p...
01-08 14:40
Phathom Pharmaceuticals shares are trading lower after the company issued Q4 guidance. The company also announced proposed public offering of common stock and pre-funded warrants.
Phathom Pharmaceuticals shares are trading lower after the company issued Q4 gu...
01-08 05:26
Phathom Pharma plans public offering after reporting preliminary 2025 results
Phathom Pharmaceuticals (PHAT) said on Wednesday it plans a public offering of common stock and pre-funded warrants, subject to market conditions, shortly after reporting preliminary fourth-quarter an...
01-08 05:19
Phathom Pharmaceuticals Expects Q4 Net Revenues Of ~$57M-$58M And FY25 Net Revenues Of ~$174.5M-$175.5M
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited
01-08 05:06
Phathom Pharmaceuticals reports Preliminary Q4 results
Phathom Pharmaceuticals press release (PHAT): Q4 Net revenues of approximately $57 million to $58 million GAAP operating expenses of approximately $59 million to $61 million Non-GAAP operating expens...
01-08 05:06
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals reported preliminary Q4 and full-year 2025 financial results. Q4 net revenues are $57-58M, GAAP operating expenses $59-61M, and non-GAAP $51-53M (excluding $8M stock-based comp). Full-year net revenues $174.5-175.5M, GAAP expenses $315.5-317.5M, and non-GAAP $284.5-286.5M (excluding $31M stock-based comp). Cash usage $6M in Q4, ending with $130M cash. VOQUEZNA surpassed 1M prescriptions in the U.S. Operating profitability ...
01-07 21:01
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
SA Quant ranks meme stocks as GameStop results miss expectations
GameStop (GME) stock fell in after-hours trading following a bigger-than-anticipated drop in third-quarter revenue. Despite the company achieving an operating income profit and showing significant ga...
2025-12-10 05:52
Barclays Initiates Coverage On Phathom Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $16
Barclays analyst Glen Santangelo initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Equal-Weight rating and announces Price Target of $16.
2025-12-10 00:08
